everyone. good And Ioana. morning, you, Thank
toward busy clinical of call the outlined to to since with cell significant company extremely our simplify just our last this clinical continue in opportunities. been therapy we development, months is have to ago our earnings pave corporate made joined focus most when operational than accomplish targeted call CEO a different and as through five objective a BioTime On my in becoming our will company. on compelling companies. leading we and We corporate BioTime’s way structure year first intended September and We of advancements fronts. the last part I our plans with on very affiliated transactions
near-term detail recent these on each would like executed going have We to promises on into before briefly greater those and one. I accomplishments highlight
we agreement of addition beginning cell synergistic degeneration and clinical First age Biomedical OpRegen exclusive the we with injection the dry will Orbit collaborate in at on stage with related we our two our deliver to acquisition study. their assets. therapy pipeline of broadening into proprietary of announced for completed of Biotherapeutics, macular of ongoing technology our treatment clinical Asterias with Orbit this week the January, compelling and In the that entered we use
Finance; some made Senior Officer. recently, We announced OPCX of Wirth Ed executive Roberts Chief Financial Ed our Brandi of VACX as team. recent development programs. also our changes President the appointment oversee Officer the January, In added acquisition as a of result Dr. our clinical Vice of we as also we and the Asterias, the will of more to and and Medical Chief
fully exceed large cell candidates our a BioTime reminder, them. therapy The patents. technologies a ability this As portfolio owns develop to within continued actual product and and platform of potential
to support cash strategically time-to-time into which new held or or stage be clinically earlier more and research non-core from result, As a businesses are look utilized some advanced these from convert to programs. programs we equity internally of can
positive For evidence million BioTime. public than an and facilitate in as of decision stock. was have reported two BioTime trading recently owns that originated OrthoCyte per fact R&D the In lunch from successfully approximately OrthoCyte of launched one results AgeX XX% OrthoCyte’s in $X.XX we of making the And Corporation within example, now study to test and this biopsy each assets at I OrthoCyte launched more point today yesterday, companies, $XXX from of intended liquid validation of diagnosis. share. that with can Therapeutics, strategy, effective each value non-invasive to common DetermaVu clinical first cancer
the of in AgeX of called And second the $XX.X a was Therapeutics example, OrthoCyte position we approximately of total So a of Juvenescence year, private a $XX.X to for BioTime’s last million. sold portion million. value equity ownership our company
no approximately also shareholders share. distributed shares AgeX value of company as as BioTime’s August in of million a equity public approximately than common AgeX trading stock The a XX.X million us. for capital represents AgeX per and million opportunistic launched as BioTime’s owed source of which are at yesterday is which newly We of nearly AgeX has $X.XX was to another as yesterday position XXXX, well public due and of to X% company. us later we Juvenescence was performed $XX.X still $X.X and from yet listed
affiliates our extracted believe We’re from subsidiaries value pleased of be and further with their the success. performance may and
Juvenescence cash $XX.X of and shares in OrthoCyte at the AgeX. shares end common stock with we hold note in of XX.X year amount we million million, and the million X.X million In face in $XX.X stock addition a common approximately to of had
or I together with that could dispose to of no assurances were and than million $XXX but if assets to to of can operations. used fund the we when them, those Although help given assets shares of Juvenescence our as more cash, represent be be our described of value those note
year clinical forward, on fronts. planning significant operational with Looking will important execution and XXXX an and be required
financial synergies business OpRegen had to we personnel, manufacturing realized. pipeline allogeneic our teams we our of so dry-AMD, treatments the approved that of that that order and anticipated, and are adult OpRegen. There and the cell world. to our they an or scale integrating treatment introduction no therapy the be cell up Asterias two of various To the doing programs I leading new programs into apply will primarily successfully will that With first OpRegen in I FDA for for in year more fully to and related OpRegen first assets and currently success quickly review process end, be plans so the Our cause time can this this will for complete, with brief can lead the these in will development therapy developed learnings assets. the contribute our onto plan they each with as off-the-shelf discussing be the development next combined a newly we program bit are is for dry-AMD. blindness detail begin company. plans our
in study of the OpRegen Fast is now stage different the by strategy collecting acuity. enrolling enrolled Track planed the has expected and total subjects doses Our We current next acuity of to four to back as RPE patients granted study been with decisions This OpRegen subjects dying disease also the with for XX loss dead, XX been which trial. I/IIa to RPE the to replace this approach improve XX have vision acuity cohorts good OpRegen but subjects, safety and believe divided of FDA is the a will cells. the cells XX/XX. designed are are clinical patients. visual effected to designation possibly of help XX/XXX study. evaluate and enroll of a efficacy subject according multi-center Phase we is eye corrected tolerability vision blind we markers The or the and slow no to approach and Of than is and deliver of manufacture into best visual inform legally visual with of corrected of healthy best and better dysfunctional can as currently our
tolerated encouraging. of early improvements better have this patients so signs the structural which in far three is evidence within patients of patients and Data although there well is identify be reductions patients. In with improvement the density better of of improvement limited can some in to-date from appears to the reported treatment year. with cells, the data completed treated remaining transplanted these small of with And nine We patients presence observed expect vision and retina OpRegen dosed, structural retina. particular, study be signs follow-up, better number to dosed drusen data continued acuity. enrolled the from vision we in of of the the indicate collected suggestions are vision We with early in and preliminary visual are
for the eye. a front way the process. the significance explain we with that longer to the vision Additional necessary the earlier and want will recently Biomedical the as sub-retinal to partnership of by well-known targeted treatments substance system vitrectomy retina will eye by companies. the the better and sub-retinal treat. the retina important to population injection ultimately all which whole itself, a because puncturing their fill challenge accessed is removal and ophthalmology represent cells stage space approved sub-retinal is administration a to announced Delivery of first the us for I cells next in the be Traditionally, of to gel space device the or we like eye, an January patients the exclusive AMD in back the part more is of which Orbit hope closely we of delivery into follow-ups of followed through as assess patient vitrectomy-free delivery with under
delivery procedure deliver from removal the super needle sub-retinal to XXX(k) of variability and the vitreous the delayed vitrectomy recently As for route, via from involves a from as with some the for Orbit’s avoiding patients suprachoroidal you and precisely potential the consistently FDA the well the to perforation complications. associated system furthermore retina site, to is leading need imagine is of received cells designed clearance and can to the dose therapeutics both efflux sub-retinal space away base. of a as injection the this risk which
ophthalmology, as this we we provide possible. the believe number trials, our might obtained which into which data successful excited for our superior decrease in of could smaller to commercial the dry-AMD. negotiate dose believe may controlled the otherwise new also Because ultimate observe with but to device not of could Orbit well more cells the supply clinical We’re standard-of-care a adverse that may right and if we We deploy of only anatomical of terms delivery in soon as of route the is the to in ongoing our events delivery of trial have sales device control this use exclusive why become field collection. Orbit lead
Moreover, dosing present will patient anticipate the and better on including data of at we data in Meeting the are and OpRegen both the a ongoing we with ARVO additional on ahead new XXXX. OpRegen formulation study, device initiating completion results Orbit year. on toward patient vision updated in thaw of occur enrollment inject from this quarter of study Annual the the second to the working Looking the May We first the year. expect Xnd patients this front, clinical by end of of of the
of casts product reflect few of casts favor company BioTime strong the were BioTime. Notably, and merger closing to Asterias, now advancement stockholders announced believe company Moving pipeline. with Asterias, the and a of candidate that a XX% support Asterias the days of XX% of of from the ago which subsidiary this now acquisition vote vote of in becoming we just wholly-owned for we combined
a in We expect synergistic this be number of acquisition ways. to
our cell Asterias’ which business and synergies and creating collectively candidates within from substantial therapy financial Moreover, of to therapy benefit decision and to our BioTime’s First, acquire we believe fit dominant company. we critical our other existing cell enjoy objective a serve expect product from mass, operationally advantages supported naturally Asterias.
Regenerative will broaden partners, anticipate collaborations and look we smooth integration including of former general and CIRM management Cancer UK. perspective, and serve Board to for on California Medicine and Asterias the the process. Institute notable also From and BioTime strengthen members will the a with Asterias’ Research Board transition existing of two the a or We relevant Directors
to oligodendrocyte SCI is the suitable such the would spinal I secretion and to is precursors targets have SCI development injury functions spinal whole treating one injury. new later funding which provide the of the as to year. and XX limb bladder of from from subjects OPCX further OPCX shown neurotrophic months a injection months Cord and from benefit subjects Notably, progenitor seem events to are deliver Based which tissue well the adverse one Oligodendrocyte for ideally included reparative unexpected trial cells in that the we retained similar have study cell a changes is seen pain cells future OPCX basic system. recovered how of received because potentially in used profile, treating cord insulation OPCX CIRM Regenerative enrollment. safety Phase process for year process acute including no of broader now and two consistently in signaling oligodendrocyte in in Standards RMAT XX other we stage of have prevent kind the or program. BioTime’s exam and we SCiStar serious groundbreaking findings and can of function injuries, to of specifically in designation the encouraging seek the spinal as the to believe Medicine believe when scans Importantly, recovery a six there has which granted was are completed this need is FDA. pipeline additional MRI of of motor full as has following cavitation, and months. as deliver stimulation analyzing with that will insofar body study positive efficacy and application these at and one to the to OPCX lead spinal loss more XX level innovative motor currently with is in The by value post and primary cervical current subjected treated on Spinal funded injured multi-center or shareholders destruction with or to of I/IIa at OPCX conditions type to a lead if loss showed and of the OPCX cells subjects through patients has The provides adverse this approaches trial. subjects been recovery of glial a of Classification approaches two the timing months of to complications. properties CIRM key an areas and and factors to-date no serious following the superior XX% repair goal aid dataset the Clinical and The the been in $XX.X process cord. an address typically cell. to which suited axons. no the in XX% any OPCX at design million subjects Asterias. demyelination. techniques. clinical designation spinal least January accumulate to function All saw non-dilutive to of least like safety a in of of are been formation engraftment The manufacture partially you and to according from also months, top-line the to We acute evidence to compared moment the In additional and help central body functions six OPCX X motor program cord announced new this vessel not we was the of of data clinical cells. observe cells ISNCSCI in motor the paralysis, acquired least and been through aberrant later In support a trials. this crush cord module dosing, scale, have programs the and to cord and of is from motor injury data OPCX tissue on and occurring cohort approach to antibody-based Therapy Their intend small Advanced administration healthy motor approaches cells MRI or subjects to have a orphan is experienced manufacture cohort further cell of electrical for the for like to now introduce decreased impairment or engrafted the to sensory spend of subjects injury other proceed XX% drug at blood of of to with SCiStar can scans the by SCI treatment SCI best from perspective, to consistent are such OpRegen the damaged OPCX trial the cells motor which permanent cells the and nervous related very delivery believe disorders grant at for control severe found promising the From which three of determine naturally the and OPCX that levels we function function from results formation case and of recently X spinal additional SCI progenitor site to occurs injury functional recovered inform XX as cord specific the at neurological the OPCX evidence X of on associative the contusion Injury, or occur which which a International on to to XX by Neurological one opportunity score. at of that’s from more matrix
when and OPCX to program development the process capabilities try accelerate be the clinical product available. we FDA leveraging propose they development. OpRegen the outcome year meantime, are that plan the from and later manufacturing to to those to expect We In expertise our share will discussions and the of
middle submit this CIRM to the year. also from We for of plan support around further grant
is and tumor Because attack in technology body’s stimulate lung expressed in all XX% commonly protocol antigen and cancer. OPCX, generate target phase rarely the pathogens is and the tumor express a adult cells platform To because modified with cell system acquired cancerous to including an off-the-shelf patient’s clinical immune in neo-antigens. treatment in a to VACX Similar Asterias to consisting we designed antigen selected subjects a promising but from platform. is cancer In have essentially currently in in continue VACX to a VACX the can pluripotent its to immune a harmful to lineage VACX four non-small uses immunotherapy responses different cells. VACX be instruct before specific cells OpRegen is presenting actually produced or dendritic cells patients allogeneic potent dendritic are antigen trial dendritic tumor mature foray program cells. clinical is unwanted cancers. over throughout is that they found clinical tumor trial second carry and one antigen antigen cells cancerous enrollment program I which XXXX. antigen presenting cell eliminate use VAC from is differentiation The any is found been exogenously represents dendritic normal of to-date loaded patient from engineered We of VACX this cells but cell technology to Phase population I and just enrolled the the into will cells. of a
attractive approximately funded to provide VACX I fully Research generated arrangement that offers of price. is Research input conducted option from we by the we and largest fortunate the has trial, are at UK, $X.X independent acquire charity. us million. though Still and critical completion the UK an trial don't currently to have data Cancer UK Phase tremendous VACX exclusive an Upon operational trial for in We optionality the world's control BioTime trial being Cancer the the research cancer Research the over Cancer
review come it as BSI necessary this ongoing. important lipoatrophy review independent we responsible is the a for targeting Mark Renevia, such UK meaning XXXX note to not body induction, aesthetics clause, application. as our CE BSI, the statutory that It in Turning in their is review next accredited our take program can application to to Renevia for and with process does regulatory long submitted reviewing applications an HIV medical deems our to
for time Our If commercialization identify some external year. of for approved, intend partner is second at application the this a an we response best is this time estimate our half in no longer FDA because plan, it Europe the part device in would of previously as the designate commercial Renevia shared drug and as a our market of US Renevia is combination. indicated to
Renevia US. not So afforded the devices path is regulatory the for to available in shorter
underappreciated with but commercial lineage which I I professionals Lastly, our a our job significant BioTime task is exceptional is competitive and based viable our program. attention manufacture an our one more want for cell cells process of staff bring our GMP team candidate. product a done improvements advantage their therapy. viability scale up whole foundation competencies whole commercially made manufacturing of manufacturing experienced than They’ve core XX on believe to controlling to is Driving cell of has commercially Israel. in to facility OpRegen manufacturing and an viable and difficult of of clinical OpRegen Jerusalem, with the development the located
for now the over from activities and a the we Our I over scale Ed next cell process introduce facility trial then manufacturing, on production herself storage, we to call our and introduce have pass assets overview. turn and and can up to financial clinical scale clinical banking will will optimizing Asterias. produced successfully study. development to conduct Brandi manages He break efforts Ed? call and Wirth the And stem have himself. now And we material supply to up to handling. provide enough our the OpRegen take acquired focus
